PRAME has already been shown to be a prime candidate for such an immunotherapy, inducing strong immune responses in healthy volunteers and patients with AML, CML, ALL and melanoma [9,54,63,64], and could potentially form a polyvalent vaccine with other cancer-testis antigens [65,66]. Here, PRAME is linked to chronic myelogenous leukemia, BCR-ABL1 positive.